Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The small study found no evidence of delayed development of antibodies in participants who experienced rebound after taking Paxlovid.
The long-acting antibody, approved for people with highly resistant HIV, can now be administered in 30 seconds.
Evusheld is used as pre-exposure prophylaxis for immunocompromised people who may not respond to COVID-19 vaccines.
Research on links between tenofovir, SARS-CoV-2 infection and COVID severity have yielded mixed results, but new study suggests it helps.
Children born to mothers on PrEP appeared to have normal growth and cognitive development.
People with both HIV and hepatitis C are at greater risk for myocardial infarction as they age, and traditional risk factors also matter.
The company will resume development of islatravir for HIV treatment but abandons monthly oral PrEP.
For the first time, gay and bi men who don’t inject drugs accounted for less than half of new cases in San Francisco.
People on opioid substitution therapy were more likely to adhere to antiretroviral treatment and achieve viral suppression.
The study, sponsored by the National Institutes of Health, will gather data on tecovirimat, or TPOXX.
Higher levels of viral antigens in the blood correlated with more severe disease.
A study in Nashville found that most women with HIV did not use birth control.
Updated Pfizer-BioNTech and Moderna bivalent boosters contain spike proteins from the original and BA.4 and BA.5 omicron variants.
Mavyret was associated with the most improvement in post-traumatic stress disorder symptoms.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.